ArticleJournal of blood medicine2026
Cellular Immunity Profile in B-Cell Non-Hodgkin Lymphoma Patients Receiving Rituximab-Based Chemotherapy.
Article in Journal of blood medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Rituximab-based chemotherapy improves outcomes in B-cell non-Hodgkin lymphoma (NHL), but may exacerbate treatment-related immunosuppression, increasing the risk of opportunistic infections. Infection prophylaxis is not routinely implemented in Indonesia. This study aimed to characterize cellular immunity changes associated with rituximab-based chemotherapy and compare them with non-rituximab chemotherapy. Patients and Methods: This prospective cohort study was conducted at two tertiary hospitals between March 2024 and October 2025. Adult patients with biopsy-confirmed B-cell NHL were enrolled in the rituximab-containing or non-rituximab chemotherapy groups. The absolute lymphocyte count, CD4 and CD8 counts, and their relative percentages were measured before treatment and after the third chemotherapy cycle. Comparative and intragroup analyses were performed using the appropriate statistical tests. Results: From 115 recruited patients, 71 completed the post-cycle-3 assessment (58 receiving rituximab-based chemotherapy, 13 receiving chemotherapy without rituximab). Baseline immune parameters were comparable between the groups. After chemotherapy, the case group demonstrated significantly lower absolute CD4 count (median 231.5 vs 423.0/µL; p=0.014), higher relative CD8 percentage (47.1% vs 34.9%; p=0.004), and a lower CD4/CD8 ratio (0.7 vs 0.9; p=0.014) compared with controls. Intragroup analysis showed significant reductions in absolute lymphocyte, CD4, and CD8 counts in the rituximab group, whereas the control group demonstrated decreases only in lymphocyte and CD8 counts, with CD4 counts largely preserved. Conclusion: Rituximab-based chemotherapy was associated with greater suppression of cellular immunity, particularly CD4 depletion and CD4/CD8 ratio reduction, than chemotherapy alone. These findings support routine immune monitoring and provide immunological evidence that may help guide future prophylaxis strategies in rituximab-treated NHL patients, especially in settings with variable prophylaxis practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.